DK3755816T3 - Fremgangsmåder til påvisning og behandling af prostatacancer - Google Patents

Fremgangsmåder til påvisning og behandling af prostatacancer Download PDF

Info

Publication number
DK3755816T3
DK3755816T3 DK19709298.4T DK19709298T DK3755816T3 DK 3755816 T3 DK3755816 T3 DK 3755816T3 DK 19709298 T DK19709298 T DK 19709298T DK 3755816 T3 DK3755816 T3 DK 3755816T3
Authority
DK
Denmark
Prior art keywords
detection
treatment
methods
prostate cancer
prostate
Prior art date
Application number
DK19709298.4T
Other languages
Danish (da)
English (en)
Inventor
Mark Kidd
Ignat Drozdov
Irvin Mark Modlin
Original Assignee
Liquid Biopsy Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Res Llc filed Critical Liquid Biopsy Res Llc
Application granted granted Critical
Publication of DK3755816T3 publication Critical patent/DK3755816T3/da

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK19709298.4T 2018-02-22 2019-02-21 Fremgangsmåder til påvisning og behandling af prostatacancer DK3755816T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862633675P 2018-02-22 2018-02-22
PCT/US2019/018878 WO2019165021A1 (en) 2018-02-22 2019-02-21 Methods for prostate cancer detection and treatment

Publications (1)

Publication Number Publication Date
DK3755816T3 true DK3755816T3 (da) 2025-04-28

Family

ID=65686083

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19709298.4T DK3755816T3 (da) 2018-02-22 2019-02-21 Fremgangsmåder til påvisning og behandling af prostatacancer

Country Status (15)

Country Link
US (3) US11410748B2 (cg-RX-API-DMAC7.html)
EP (2) EP3755816B1 (cg-RX-API-DMAC7.html)
JP (2) JP7662337B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260018206A (cg-RX-API-DMAC7.html)
CN (2) CN119932188A (cg-RX-API-DMAC7.html)
AU (2) AU2019224025B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016989A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091647A1 (cg-RX-API-DMAC7.html)
DK (1) DK3755816T3 (cg-RX-API-DMAC7.html)
ES (1) ES3023842T3 (cg-RX-API-DMAC7.html)
IL (1) IL276748A (cg-RX-API-DMAC7.html)
MX (2) MX2020008702A (cg-RX-API-DMAC7.html)
PL (1) PL3755816T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202007922XA (cg-RX-API-DMAC7.html)
WO (1) WO2019165021A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901819A (zh) 2019-10-10 2022-08-12 液体活检研究有限责任公司 用于生物样品和rna稳定化的组合物、方法和试剂盒
JP7757291B2 (ja) * 2020-02-06 2025-10-21 オンコホスト リミテッド 治療法応答の機械学習予測
WO2023017525A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
JP2025534688A (ja) 2022-10-12 2025-10-17 リキッド バイオプシー リサーチ リミティド ライアビリティ カンパニー 唾液において前立腺癌を検出するための方法
GB2623570B (en) * 2022-10-21 2025-07-23 Wobble Genomics Ltd Method and products for biomarker identification
KR102891032B1 (ko) * 2022-12-29 2025-12-03 재단법인대구경북과학기술원 혈액 단구세포 전사체 생체표지자를 이용한 전이성 전립선암 진단용 바이오마커 및 이의 용도
CN116908444B (zh) * 2023-09-13 2023-12-19 中国医学科学院北京协和医院 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用
CN119964650B (zh) * 2024-12-24 2025-09-30 深圳大学 一种基于集成学习的基因调控网络推断方法和系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007271232A1 (en) * 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
IL243203A (en) * 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
DK3179393T3 (da) * 2012-01-31 2020-07-27 Genomic Health Inc Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft
HK1210230A1 (en) * 2012-07-20 2016-04-15 戴格努生命科学公司 Methods, kits and compositions for providing a clinical assessment of prostate cancer
US10081842B2 (en) * 2012-08-07 2018-09-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer gene expression profiles
KR20150110477A (ko) * 2012-11-20 2015-10-02 파디아 에이비 공격적인 전립선 암의 존재 또는 부존재를 나타내는 방법
PL2945628T3 (pl) * 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
JP2016521966A (ja) * 2013-03-15 2016-07-28 メタマーク ジェネティクス, インコーポレイテッド 癌の予後のための組成物および方法
US20160130661A1 (en) * 2013-06-13 2016-05-12 University Of South Australia Methods for detecting prostate cancer
CA2920429C (en) 2013-08-06 2021-11-16 Exosome Diagnostics, Inc. Urine biomarker cohorts, gene expression signatures, and methods of use thereof
EP3214444A1 (en) * 2016-03-04 2017-09-06 AIT Austrian Institute of Technology GmbH Prostate cancer diagnostic method and means

Also Published As

Publication number Publication date
ES3023842T3 (en) 2025-06-03
SG11202007922XA (en) 2020-09-29
AU2019224025A1 (en) 2020-09-10
EP3755816A1 (en) 2020-12-30
US20260066046A1 (en) 2026-03-05
US20230298695A1 (en) 2023-09-21
US20190259471A1 (en) 2019-08-22
JP2021514624A (ja) 2021-06-17
AU2025238057A1 (en) 2025-11-27
MX2020008702A (es) 2020-09-25
CN112673115B (zh) 2025-02-18
KR102921718B1 (ko) 2026-02-03
KR20260018206A (ko) 2026-02-06
AU2019224025B2 (en) 2025-06-26
IL276748A (en) 2020-10-29
EP3755816B1 (en) 2025-02-12
WO2019165021A1 (en) 2019-08-29
CN112673115A (zh) 2021-04-16
KR20200123450A (ko) 2020-10-29
CN119932188A (zh) 2025-05-06
BR112020016989A2 (pt) 2020-12-29
CA3091647A1 (en) 2019-08-29
JP2025096376A (ja) 2025-06-26
EP4538393A3 (en) 2025-07-02
JP7662337B2 (ja) 2025-04-15
MX2025000449A (es) 2025-03-07
US11410748B2 (en) 2022-08-09
PL3755816T3 (pl) 2025-06-30
EP4538393A2 (en) 2025-04-16

Similar Documents

Publication Publication Date Title
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
DK3755816T3 (da) Fremgangsmåder til påvisning og behandling af prostatacancer
DK3902803T3 (da) Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft
DK3336197T3 (da) Epigenetiske markører og relaterede fremgangsmåder og midler til detektion og behandling af ovariekræft
DK3455259T3 (da) Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling
IL269150A (en) Compositions and methods for treating cancer
IL268814A (en) Compositions and methods for treatment of cancer
DK3426777T3 (da) Kombinationsvektorer og fremgangsmåder til behandling af cancer
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
IL263224A (en) Methods and compositions for treating cancers
EP3806724A4 (en) DETECTION AND CHARACTERIZATION OF CANCERUS TUMORS
DK3331900T3 (da) Peptider og kombination af peptider til anvendelse ved immunterapi mod prostatacancer og andre cancere
PL3443350T3 (pl) Sposoby monitorowania i leczenia nowotworu
DK3277842T3 (da) Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
DK3778592T3 (da) PSMA-målrettet radiolægemiddel til diagnosticering og behandling af prostatacancer
DK3988541T3 (da) Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse
DK3609497T3 (da) Niraparib, abirateronacetat og prednison til behandling af prostatakræft
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
DK3852533T3 (da) Pyridazinoner og fremgangsmåder til anvendelse deraf
DK3545140T3 (da) Fremgangsmåde til recirkulering af vand og vandrecirkuleringsapparatur
IL269157A (en) Compositions and methods for treating cancer
DK3325623T3 (da) Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer
DK3743534T3 (da) Fremgangsmåde til påvisning af coloncancer og behandlingsovervågning